REQUEST A REP
Dosing Mobile_Page Divider_water 2 (1)

MYCAPSSA Treats Acromegaly With Twice-Daily Dosing

Make Your Move to MYCAPSSA
Example of treatment schedule:
arrow-desktop-image arrow-mobile-image
Start
iSSA
As early as month 1
~Month 2
~Month 3 and beyond
MYCAPSSA may be initiated as soon as the patient shows a response and is able to tolerate treatment with octreotide or lanreotide.1
*In patients who respond to and tolerate treatment with iSSA.
†Based on the evaluation of IGF-I, signs, and symptoms.
Treat Acromegaly and Its Symptoms All Day, Every Day1
MYCAPSSA offers a flexible dosing schedule.
  • First and second doses do not need to be taken exactly 12 hours apart or at the same time each day
  • MYCAPSSA should be taken 1 hour before or 2 hours after meals
  • Developing a habit for taking morning and evening doses may help patients stay compliant
Here is an example:
doseguide Group 1741
mycapssa_capsule CHI_mycapssa_package_CS_300_Silo 2
Each wallet of MYCAPSSA comes with 28 capsules. Each MYCAPSSA capsule is 20 mg.
Once opened, MYCAPSSA wallets do not need to be refrigerated, and may be stored at room temperature for 30 days.1‡
‡Opened wallets may be stored at room temperature (68° to 77°F) for up to 1 month.
Watch Becky as she talks about her routine to take MYCAPSSA.
Becky
Titrating MYCAPSSA Is Straightforward1
Evaluate IGF-I, signs, and symptoms every 2 weeks during the dose titration period. Adjust dose if needed.1
Example of titration schedule1:
Titration mobile 1
Once the maintenance dosage of MYCAPSSA is achieved, monitor IGF-I levels and acromegaly signs and symptoms periodically.
The majority of patients in clinical trials required dose escalation.2,3

Adverse events were not dose related.4

IGF-I, insulin-like growth factor 1.
Let’s Connect
Get in touch with a MYCAPSSA Sales Representative.
REQUEST A REP

Important Safety Information

Contraindications

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.


Warnings and Precautions

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.


Adverse Reactions

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.


Drug Interactions

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.


Pregnancy

Advise premenopausal females of the potential for an unintended pregnancy.

Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information, including Medication Guide.

Indication

Indication and usage

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Important Safety Information

Contraindications

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.


Warnings and Precautions

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.


Adverse Reactions

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.


Drug Interactions

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.


Pregnancy

Advise premenopausal females of the potential for an unintended pregnancy.

Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information, including Medication Guide.

Indication

Indication and usage

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

REFERENCES: 1. MYCAPSSA [package insert]. Chiesi USA, Inc. 2024. 2. Samson SL, et al. J Clin Endocrinol Metab. 2020;105(10):1-13. 3. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2022;10(2):102-111. 4. Melmed S, et al. J Clin Endocrinol Metab. 2015;100(4):1699-1708.